Shigeru Marubashi, Hiroaki Nagano, Hidetoshi Eguchi, Hiroshi Wada, Tadafumi Asaoka, Yoshito Tomimaru, Akira Tomokuni, Koji Umeshita, Yuichiro Doki, Masaki Mori – 19 December 2015 – Small‐for‐size graft syndrome is an inevitable complication in living donor liver transplantation (LDLT). We hypothesized that graft weight (GW) measured after graft procurement is one of the variables predicting postoperative graft function. A total of 138 consecutive recipients of adult‐to‐adult LDLT between March 1999 and October 2014 were included in this study.

Jie Wei, Lei Fu, Shi‐fang Peng – 19 December 2015

Hui Chen, Fanny Turon, Virginia Hernández‐Gea, Josep Fuster, Angeles Garcia‐Criado, Marta Barrufet, Anna Darnell, Constantino Fondevila, Juan Carlos Garcia‐Valdecasas, Juan Carlos Garcia‐Pagán – 19 December 2015 – Portal vein thrombosis (PVT) occurs in approximately 2%‐26% of the patients awaiting liver transplantation (LT) and is no longer an absolute contraindication for LT. Nearly half of PVT cases are accidentally found during the LT procedure. The most important risk factor for PVT development in cirrhosis may be the severity of liver disease and reduced portal blood flow.

Maristela Pinheiro Freire, Ligia Câmera Pierrotti, Isabel Cristina Villela Soares Oshiro, Patrícia Rodrigues Bonazzi, Larissa Marques de Oliveira, Anna Silva Machado, Inneke Marie Van Der Heijden, Flavia Rossi, Silvia Figueiredo Costa, Luiz Augusto Carneiro D'Albuquerque, Edson Abdala – 19 December 2015 – Infection with carbapenem‐resistant Acinetobacter baumannii (CRAB) after liver transplantation (LT) is associated with high mortality.

Kyoji Ito, Nobuhisa Akamatsu, Keigo Tani, Daisuke Ito, Junichi Kaneko, Junichi Arita, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Norihiro Kokudo – 19 December 2015 – Special care must be taken in hepatic vein reconstruction to avoid outflow block in living donor liver transplantation (LDLT) with a right liver graft. We have used cryopreserved homologous veins to reconstruct the right hepatic vein (RHV), middle hepatic vein (MHV), MHV tributaries (V5 and V8), and inferior right hepatic vein (IRHV).

Yoshifumi Iwagami, Chiung‐Kuei Huang, Mark J. Olsen, John‐Michael Thomas, Grace Jang, Miran Kim, Qiushi Lin, Rolf I. Carlson, Carl E. Wagner, Xiaoqun Dong, Jack R. Wands – 19 December 2015 – Aspartate β‐hydroxylase (ASPH) is an enzyme overexpressed in human hepatocellular carcinoma (HCC) tumors that participates in the malignant transformation process. We determined if ASPH was a therapeutic target by exerting effects on cellular senescence to retard HCC progression.

Yu Guo, Jing Wang, Lu Zhang, Shunli Shen, Ruomi Guo, Yang Yang, Wenjie Chen, Yiru Wang, Guihua Chen, Xintao Shuai – 17 December 2015 – Because the primary surgical treatment options for hepatocellular carcinoma (HCC)—including hepatic resection and liver transplantation—often fail due to recurrence and metastasis, identifying early prognostic biomarkers and therapeutic targets for HCC is of great importance.

Neil Mehta, Francis Y. Yao – 17 December 2015

Jorge A. Bezerra – 17 December 2015

Mostafa M. Sira, Ahmad M. Sira – 17 December 2015